Network Portfolio Roadmap
Submitted by Anonymous (not verified) on 26 May 2026 - 8:27
Network Portfolio Roadmap
Human medicines European public assessment report (EPAR): Ucedane, carglumic acid, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 26 May 2026 - 8:19
Human medicines European public assessment report (EPAR): Ucedane, carglumic acid, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised
Questions and answers on periodic safety update report single-assessment (PSUSA): Guidance document for assessors
Submitted by Anonymous (not verified) on 22 May 2026 - 15:00
Questions and answers on periodic safety update report single-assessment (PSUSA): Guidance document for assessors
Guideline on good pharmacovigilance practices (GVP): Module VII – Periodic safety update report - Explanatory note
Submitted by Anonymous (not verified) on 22 May 2026 - 14:40
Guideline on good pharmacovigilance practices (GVP): Module VII – Periodic safety update report - Explanatory note
Human medicines European public assessment report (EPAR): Adempas, riociguat, Date of authorisation: 27/03/2014, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 22 May 2026 - 14:25
Human medicines European public assessment report (EPAR): Adempas, riociguat, Date of authorisation: 27/03/2014, Revision: 18, Status: Authorised
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 19-21 May 2026
Submitted by Anonymous (not verified) on 22 May 2026 - 14:12
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 19-21 May 2026
Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 22 May 2026 - 14:05
Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 10, Status: Authorised
Summary of opinion: Respivac aMPV (previously Respivac TRT), 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 14:04
Summary of opinion: Respivac aMPV (previously Respivac TRT), 21/05/2026 Positive
Scientific and technical recommendations: Veterinary Medicines Regulation
Submitted by Anonymous (not verified) on 22 May 2026 - 14:01
Scientific and technical recommendations: Veterinary Medicines Regulation
EC request to EMA for guidance on scientific issues in relation to Articles 107(6) and 114(3) of Regulation (EU) 2019/6
Submitted by Anonymous (not verified) on 22 May 2026 - 14:00
EC request to EMA for guidance on scientific issues in relation to Articles 107(6) and 114(3) of Regulation (EU) 2019/6